<DOC>
	<DOC>NCT00363727</DOC>
	<brief_summary>This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa for less than 2 years.</brief_summary>
	<brief_title>Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Must be on 600mg or less of levodopa therapy for two years or less. Must be on a stable dose of levodopa therapy for at least 4 weeks prior to screening. Current or past history of Dyskinesia. State of dementia or have a MMSE score &lt; 26 at screening.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>dyskinesia</keyword>
	<keyword>SINEMET</keyword>
	<keyword>Parkinson's disease</keyword>
	<keyword>controlled release ropinirole</keyword>
</DOC>